Free Trial
NASDAQ:ZBIO

Zenas Biopharma (ZBIO) Stock Price, News & Analysis

Zenas Biopharma logo
$10.35 -0.21 (-1.99%)
As of 09:59 AM Eastern

About Zenas Biopharma Stock (NASDAQ:ZBIO)

Key Stats

Today's Range
$10.03
$10.56
50-Day Range
$6.77
$11.92
52-Week Range
$5.83
$26.25
Volume
17,928 shs
Average Volume
180,220 shs
Market Capitalization
$432.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.67
Consensus Rating
Buy

Company Overview

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Receive ZBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zenas Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ZBIO Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
See More Headlines

ZBIO Stock Analysis - Frequently Asked Questions

Zenas Biopharma's stock was trading at $7.90 at the start of the year. Since then, ZBIO shares have increased by 31.0% and is now trading at $10.35.
View the best growth stocks for 2025 here
.

Zenas Biopharma Inc (NASDAQ:ZBIO) issued its earnings results on Thursday, May, 15th. The company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($1.15) by $0.35. The business earned $10 million during the quarter, compared to analysts' expectations of $5 million.

Zenas Biopharma (ZBIO) raised $225 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 13,235,294 shares at $17.00 per share.

Zenas Biopharma's top institutional investors include Wellington Management Group LLP (2.09%), Charles Schwab Investment Management Inc. (0.28%), Jefferies Financial Group Inc. (0.11%) and Nuveen LLC (0.08%).

Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas Biopharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI).

Company Calendar

Last Earnings
5/15/2025
Today
5/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZBIO
Previous Symbol
NASDAQ:ZBIO
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.67
High Stock Price Target
$45.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+254.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$15 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$432.98 million
Optionable
N/A
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ZBIO) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners